Medicine & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Advanced Cell Technology
Advanced Cell Technology announces settlement of patent interference action
October 13th, 2006
Advanced Cell Technology, Inc., (ACTC) (ACT) announced that it has settled a patent dispute involving certain nuclear transfer cloning patents and patent applications owned or licensed by the University of Massachusetts (UMass), Roslin Institute (Roslin), Geron Corp. (GERN) (Geron), Start Licensing, Inc., (Start) and ACT. The dispute involved appeals to the U.S. District Court by ACT and UMass that sought to overturn rulings by the U.S. Patent and Trademark Office against ACT and UMass in patent interference numbers 104,746 and 105,192. The underlying interference proceedings centered around patent applications owned by Roslin against U.S. Patents...
Source: Medicine & Law Weekly (2006-10-13)
|
